SCHEMBL3270072

SCHEMBL3270072

NC(=O)COC(=O)NC1CCN(c2cccc(-c3ccc(F)cc3)n2)CC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN9A Q15858 4/20 0.44
CNR1 P21554 1/20 0.43
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
CHRM4 P08173 1/20 0.41
CYP11B2 P19099 2/20 0.40
PRKAA2 P54646 1/20 0.39
HTR1A P08908 1/20 0.39
DRD2 P14416 1/20 0.39
DRD4 P21917 1/20 0.39
HTR2A P28223 1/20 0.39
HTR2C P28335 1/20 0.39
HTR7 P34969 1/20 0.39
DRD3 P35462 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
GAA P10253 1/20 0.39
CYP2C9 P11712 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3266883 0.91 CKS1B (0.47) CNR1SMN1; SMN2CKS1BSKP1SKP2
SCHEMBL3266878 0.87 CKS1B (0.45) SCN9ACNR1NPC1RAB9ASMN1; SMN2
SCHEMBL3265618 0.85 CNR1 (0.41) SCN9ACNR1NPC1RAB9ASMN1; SMN2
SCHEMBL1730207 0.82 CNR1 (0.50) SCN9ACNR1NPC1RAB9ASMN1; SMN2
SCHEMBL3265677 0.82 TDO2 (0.51) L3MBTL1CHRM4CKS1BSKP1SKP2
SCHEMBL3268988 0.81 HSD11B1 (0.41) CHRM4CYP1A2CKS1BSKP1SKP2
SCHEMBL3265674 0.78 HTR1A (0.42) CNR1CHRM4HTR1ADRD2HTR7
SCHEMBL240063 0.77 CKS1B (0.48) CNR1CKS1BSKP1SKP2
SCHEMBL3265609 0.76 CKS1B (0.41) CNR1CHRM4CKS1BSKP1SKP2
SCHEMBL27629096 0.76 CKS1B (0.53) CNR1SMN1; SMN2CKS1BSKP1SKP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120004207-A1 THERAPEUTIC USES OF DERIVATIVES OF PIPERIDINYL-AND PIPERIDINYL-ALKYL CARBAMATES SANOFI-AVENTIS (FR) 2012-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120004207-A1 THERAPEUTIC USES OF DERIVATIVES OF PIPERIDINYL-AND PIPERIDINYL-ALKYL CARBAMATES CLCN2, CLIC1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 SCN9A 1300/4885CNR1 20/4885NPC1 229/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.